Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Bimiralisib (PQR309) in Relapsed or Refractory Lymphoma
2016-000125-38Phase 2Terminated
- Sponsor
- PIQUR Therapeutics AG
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bimiralisib in lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by PIQUR Therapeutics AG. Primary endpoint: Primary efficacy endpoint. Started Feb 2016; status: terminated.
02
Drugs
bimiralisib
03
Conditions
lymphomachronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2016-000125-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000125-38.